Hostname: page-component-84b7d79bbc-2l2gl Total loading time: 0 Render date: 2024-07-30T08:08:14.247Z Has data issue: false hasContentIssue false

Melatonin treatment of non-epileptic myoclonus in children

Published online by Cambridge University Press:  01 April 1999

James E Jan
Affiliation:
Division of Developmental Pediatrics, University of British Columbia, Vancouver, Canada.
Mary B C Connolly
Affiliation:
Division of Child Neurology, University of British Columbia, Vancouver, Canada.
Don Hamilton
Affiliation:
Pharmacy Department, Children's and Women's Health Centre of British Columbia, Vancouver, Canada.
Roger D Freeman
Affiliation:
Department of Psychiatry, University of British Columbia, Vancouver, Canada.
Moshe Laudon
Affiliation:
Neurim Pharmaceuticals, Tel Aviv, Israel.
Get access

Abstract

Oral melatonin (MLT) has been used by our Vancouver research group in the treatment of paediatric sleep disorders since 1991; slightly over 200 children, mainly with multiple disabilities, who frequently had seizures, have been treated. Three children with markedly delayed sleep onset due to recurring myoclonus were also referred for MLT treatment: two had non-epileptic, and one had epileptic and non-epileptic myoclonus. Low doses of oral MLT (3 to 5 mg) unexpectedly abolished their myoclonus and allowed them to sleep. There were no adverse effects. It appears that certain types of myoclonus, which might be resistant to conventional anticonvulsant medications, may respond to MLT but the mechanism of action is unclear. Further research on this novel treatment is urgently needed.

Type
Original Articles
Copyright
© 1999 Mac Keith Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)